Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis & Investment Frameworks
Supernus Pharmaceuticals, Inc. (SUPN) stock analysis on Invetso. Review Supernus Pharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Supernus Pharmaceuticals, Inc. Company Overview
- Exchange: NASDAQ Global Market
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: US
Supernus Pharmaceuticals, Inc. Key Financial Metrics
- Market Cap: $2.40B
- Revenue: $718.95M
- ROE: -10.42%
- ROIC: -9.12%
- Dividend Yield: N/A
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
Supernus Pharmaceuticals, Inc. Investment Frameworks
Invetso analyzes Supernus Pharmaceuticals, Inc. (SUPN) across the following frameworks:
- Supernus Pharmaceuticals, Inc. 10Y Growth Potential
- Supernus Pharmaceuticals, Inc. Scenario Analysis
- Supernus Pharmaceuticals, Inc. Risks & Opportunities
- Supernus Pharmaceuticals, Inc. Economic Moat
- Supernus Pharmaceuticals, Inc. Business Model
- Supernus Pharmaceuticals, Inc. Management
- Supernus Pharmaceuticals, Inc. SWOT Analysis
- Supernus Pharmaceuticals, Inc. Porter's 5 Forces
- Supernus Pharmaceuticals, Inc. PESTLE Analysis
- Supernus Pharmaceuticals, Inc. ESG Analysis